TuHURA Biosciences, Inc./NV
HURA evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $130.6M
- Lead Asset:
- ifx2.0 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for HURA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HURA
TuHURA Biosciences, Inc. (HURA) is a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, with a lead Phase III program in Merkel cell carcinoma and a recently cleared IND for a VISTA-inhibiting antibody in AML.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$130.6M
Cash Runway
—
Lead Asset
ifx2.0 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for TuHURA Biosciences, Inc./NV.
TuHURA Biosciences, Inc. (HURA) is a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, with a lead Phase III program in Merkel cell carcinoma and a recently cleared IND for a VISTA-inhibiting antibody in AML.
- Cash & equivalents of $1.0M as of 2026-06-30 [sec].
- Net income of -$9.2M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $18.5M as of 2026-06-30 [sec].
- Phase III trial of IFx-Hu2.0 in first-line advanced Merkel cell carcinoma is ongoing [news · published 2026-08-14].
- FDA cleared IND for TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of AML and other blood-related cancers on 2026-09-14 [news · published 2026-09-14].
What works
- Lead program IFx-Hu2.0 has advanced to a Phase III randomized, double-blind, placebo-controlled trial in Merkel cell carcinoma, a late-stage milestone [catalyst].
- The company secured a $50 million loan facility, which management believes is sufficient to provide a cash runway [news · published 2026-05-26].
- FDA clearance of the IND for TBS-2025 opens a new clinical pathway in AML and blood-related cancers, expanding the pipeline beyond solid tumors [news · published 2026-09-14].
What to weigh
- Cash position is very low at $1.0M as of 2026-06-30, indicating a need for near-term financing or revenue [sec].
- Net loss of $9.2M in the most recent quarter (ended 2026-06-30) reflects ongoing operating deficits [sec].
- The VISTA-inhibitor space is crowded, with at least 363 competitors including Merck and other large pharma players [pipeline].
- Phase III readout for IFx-Hu2.0 is not expected until early 2026, leaving a period of binary event risk [news · published 2025-11-18].
From the filings
Quoted directly from source documents.
FDA clearance of IND for TBS-2025 in AML and blood-related cancers
“the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.”
News · September 14, 2026
Phase III trial of IFx-Hu2.0 in Merkel cell carcinoma is ongoing
“A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma”
Catalysts
Catalyst timeline
- 2025-10-01 · Phase1_Start: IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma — Initiation of a Phase 1 study for IFx-Hu2.0 in Merkel cell carcinoma.
- 2025-12-11 · Phase3_Start: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma — Start of the pivotal Phase 3 trial for IFx-Hu2.0 in Merkel cell carcinoma.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash & equivalents of only $1.0M as of 2026-06-30 may require near-term financing [sec].
- Ongoing net losses — Net loss of $9.2M in the most recent quarter (ended 2026-06-30) indicates continued cash burn [sec].
- Competitive VISTA landscape — 363 competitors in the VISTA-inhibitor space, including Merck and other large pharma [pipeline].
- Binary Phase III outcome — Phase III readout for IFx-Hu2.0 expected in early 2026, creating a binary event risk [news · published 2025-11-18].
What to watch
- Phase III readout for IFx-Hu2.0 in Merkel cell carcinoma, expected early 2026 [news · published 2025-11-18].
- Initiation of Phase Ib/II trial for TBS-2025 in AML following IND clearance [news · published 2026-09-14].
- Company's ability to secure additional financing given low cash position [sec].
- Presentation at H.C. Wainwright conference on 2026-09-08 may provide pipeline updates [news · published 2026-09-08].
Sources: Catalysts · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run TuHURA Biosciences, Inc./NV through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TuHURA Biosciences, Inc./NV facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.72 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
88
Total value held
$16.8M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,450,256 | $4.4M |
| vanguard capital management llc | 2,074,228 | $3.7M |
| geode capital management, llc | 986,922 | $1.8M |
| aqr capital management llc | 607,168 | $1.1M |
| state street corp | 512,913 | $918K |
| northern trust corp | 298,187 | $534K |
| vanguard fiduciary trust co | 287,133 | $514K |
| vanguard portfolio management llc | 253,641 | $454K |
| bank of new york mellon corp | 211,568 | $379K |
| apollon wealth management, llc | 158,010 | $283K |
Showing top 10 of 88 institutional holders of TuHURA Biosciences, Inc./NV. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 16.8%
- Days to cover
- 6.3
- Shares short
- 8,260,038
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HURA short interestGovernance
Frequently asked questions
What is the AI investment thesis for TuHURA Biosciences, Inc./NV?
TuHURA Biosciences, Inc. (HURA) is a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, with a lead Phase III program in Merkel cell carcinoma and a recently cleared IND for a VISTA-inhibiting antibody in AML.
What is TuHURA Biosciences, Inc./NV's lead drug candidate?
TuHURA Biosciences, Inc./NV's most advanced tracked candidate is ifx2.0 (Phase 3).
Who is the CEO of TuHURA Biosciences, Inc./NV?
Dr. James A. Bianco M.D. is the chief executive officer of TuHURA Biosciences, Inc./NV (HURA).
Where is TuHURA Biosciences, Inc./NV headquartered?
TuHURA Biosciences, Inc./NV (HURA) is headquartered in Tampa, FL, United States.
What therapeutic areas does TuHURA Biosciences, Inc./NV focus on?
TuHURA Biosciences, Inc./NV develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.